| Literature DB >> 32039564 |
Jialing Rong1, Xianqun Xu1, Yang Xiang1, Guohua Yang2, Xinliang Ming1, Siying He1, Bin Liang1, Xiaokang Zhang1, Fang Zheng1.
Abstract
Numerous studies have demonstrated that thioredoxin-interacting protein (TXNIP) expression of peripheral blood leucocytes is increased in coronary artery disease (CAD). However, the molecular mechanism of this phenomenon remained unclear. DNA methylation plays important roles in the regulation of gene expression. Therefore, we speculated there might be a close association between the expression of TXNIP and methylation. In this study, we found that compared with controls, DNA methylation at cg19693031 was decreased in CAD, while mRNA expressions of TXNIP and inflammatory factors, NLRP3, IL-1β, IL-18, were increased. Methylation at cg19693031 was negatively associated with TXNIP expression in the cohort, THP-1 and macrophages/foam cells. Furthermore, Transwell assay and co-cultured adhesion assay were performed to investigate functions of TXNIP on the migration of THP-1 or the adhesion of THP-1 on the surface of endothelial cells, respectively. Notably, overexpressed TXNIP promoted the migration and adhesion of THP-1 cells and expressions of NLRP3, IL-18 and IL-1β. Oppositely, knock-down TXNIP inhibited the migration and adhesion of THP-1 and expressions of NLRP3, IL-18. In conclusion, increased TXNIP expression, related to cg19693031 demethylation orientates monocytes towards an inflammatory status through the NLRP3 inflammasome pathway involved in the development of CAD.Entities:
Keywords: coronary artery disease; inflammation; methylation; monocytes; oxidative stress; thioredoxin-interacting protein
Year: 2020 PMID: 32039564 PMCID: PMC7131938 DOI: 10.1111/jcmm.15045
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Clinical characteristics of the CAD and control (non‐CAD) individuals
| Clinical data | Control (n = 127) | CAD(n = 131) |
|
|---|---|---|---|
| Age (y) | 61 (58‐67) | 63 (58‐70) | .275 |
| Male, gender | 68 (53.5) | 75 (57.3) | .549 |
| WBC | 5.69 (5.11‐6.48) | 5.83 (5.13‐7.3) | .197 |
| NEUT%**** |
|
| < |
| LYMPH%**** |
|
| < |
| MONO%* |
|
|
|
| TC (mmol/L) | 4.6 (4.15‐4.90) | 4.38 (3.47‐5.02) | .109 |
| TG**** (mmol/L) |
|
| < |
| HDL‐C**** (mmol/L) |
|
| < |
| LDL‐C** (mmol/L) |
|
|
|
| Diabetes****, n (%) |
|
| < |
| Hypertension****, n (%) |
|
| < |
| Smoking**, n (%) |
|
|
|
| Hyperlipidemia****, n (%) |
|
| < |
| FPG (mmol/L)**** |
|
| < |
| TXNIP mRNA level* |
|
|
|
The results are presented as mean ± SD (standard deviation) or as median (inter‐quartile range); Italic letters show the significant associations and their P‐values.
Abbreviations: FPG, fasting plasma glucose; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; LYMPH, lymphocyte; MONO, monocyte; NEUT, neutrophil; TC, total cholesterol; TG, triglyceride; WBC, white blood cell.
Two‐tailed Student's t test.
Non‐parametric test (Mann‐Whitney U test).
χ2 test.
The CAD patients are consisted of 40 (30.5%) myocardial infarction, 34 (26%) stable angina pectoris, and 57 (43.5%) unstable angina pectoris, respectively.
*P < .05, **P < .01, ***P < .001 and ****P < .0001.
Clinical characteristics of the CAD and control (non‐CAD) individuals involved in pyrosequencing
| Characteristics | Control (no‐CAD, n = 54) | CAD(n = 54) |
|
|---|---|---|---|
| Age (y) | 61 (54.75‐65) | 62.5 (56.75‐70.25) | .166 |
| Male, n (%) | 32 (59.3) | 29 (53.7) | .56 |
| Systolic blood pressure | 128 (117.25‐142) | 137 (118.5‐153.75) | .125 |
| Diastolic blood pressure | 79 (71.25‐88) | 80 (73‐89.75) | .33 |
| FPG* (mmol/L) |
|
|
|
| TC**** (mmol/L) |
|
| < |
| TG* (mmol/L) |
|
|
|
| HDL‐C**** (mmol/L) |
|
| < |
| LDL‐C** (mmol/L) |
|
|
|
| Diabetes**, n (%) |
|
|
|
| Hypertension****, n (%) |
|
| < |
| Smoking*, n (%) |
|
|
|
| cg19693031 methylation* (%) |
|
|
|
| TXNIP mRNA level* |
|
|
|
The results are presented as mean ± SD (standard deviation) or as median (inter‐quartile range); Italic letters show the significant associations and their P‐values.
Abbreviations: FPG, fasting plasma glucose; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.
Two‐tailed Student's t test.
Non‐parametric test (Mann‐Whitney U test).
χ2 test.
*P < .05, **P < .01, ***P < .001 and ****P < .0001.
Figure 1Negative correlation with methylation at cg19693031 and mRNA expression of TXNIP in PBLs and 5‐Aza treated THP‐1 cells. A, The DNA methylation levels of cg19693031 (in the 3′ UTR of TXNIP) were detected by pyrosequencing in the PBLs of CAD patients (n = 54) and controls (n = 54). B, The mRNA levels of TXNIP were detected by qPCR in the PBLs of CAD and controls. C‐F, The correlations of DNA methylation at cg19693031 and mRNA level of TXNIP (C), the level of TC (D), the level of GLU (E) in the plasma and the age (F) of all participates. G, The DNA methylation levels of cg19693031 were detected by bisulphite sequencing in THP‐1 treated with 5‐Aza at different concentrations. H, The mRNA levels of TXNIP were detected by qPCR in THP‐1 treated with 5‐Aza at different concentrations. All values are the averages of three independent experiments, and the results are present as the means ± SDs. P < .05 was defined as significant. *P < .05; **P < .01. r: Spearman correlation coefficient; 5‐Aza: 5‐azacytidine
Figure 2The mRNA expression of TXNIP, NLRP3, IL‐1β and IL‐18 in PBLs of CAD (n = 131) and control (n = 128) individuals. A‐D, The mRNA expression of TXNIP (A), NLRP3 (B), IL‐1β (C) and IL‐18 (D) was detected by qPCR in PBLs of CAD and control individuals. E, Associations of TXNIP and NLRP3 in all of two groups. F, Associations of TXNIP and IL‐18 in all of two groups. All values are the average of at least three replicates, and the results are present as the means ± SDs. P < .05 was defined as significant. *P < .05; **P < .01; ***P < .001; ****P < .0001. r: Spearman correlation coefficient
Figure 3Overexpression of TXNIP increased TXNIP expression and promoted monocyte activation. A, Fluorescent and white light images of THP‐1 cells after infected with TXNIP‐lentivirus or CON‐lentivirus. B and C, The relative TXNIP mRNA (B) and protein (C) expression was determined by RT‐qPCR and Western blotting in THP‐1 cells transfected with TXNIP‐lentivirus or with CON‐lentivirus in three independent experiments. D, The relative mRNA expression of NLRP3, IL‐18 and 1β was determined by RT‐qPCR in three independent experiments. E, The migration capacity of THP‐1 cells in three groups was assessed using a fluorescence microscope (100×). F, The adhesive capacity of THP‐1 cells in three independent experiments was assessed by Transwell migration assay with an inverted microscope (100×). Results are the means ± SDs for three independent experiments. P < .05 was defined as significant. *P < .05; **P < .01
Figure 4Knock‐down of TXNIP decreased TXNIP expression and inhibited monocyte activation. A, Fluorescent and white light images of THP‐1 cells after infected with TXNIP‐shRNA1, TXNIP‐shRNA2 or CON‐shRNA. B and C, The relative TXNIP mRNA (B) and protein (C) expression was determined by RT‐qPCR and Western blotting in THP‐1 cells transfected with TXNIP‐shRNA1, TXNIP‐shRNA2 or with CON‐shRNA in three independent experiments. D, The relative mRNA expression of NLRP3, IL‐18 and 1β was determined by RT‐qPCR in three independent experiments. E, The migration capacity of THP‐1 cells in three groups was assessed using a fluorescence microscope (100×). F, The adhesive capacity of THP‐1 cells in three groups was assessed by Transwell migration assay with an inverted microscope (100×). Results are the means ± SDs for three independent experiments. P < .05 was defined as significant. *P < .05; **P < .01